SCHEMBL4669377

SCHEMBL4669377

CCOC(=O)C1=C(C)N=c2s/c(=C/c3ccc(OC(C)=O)cc3)c(=O)n2C1c1ccc(OC)c(OC)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.81
NPSR1 Q6W5P4 2/20 0.81
MEN1 O00255 10/20 0.70
KMT2A Q03164 10/20 0.70
DNMT1 P26358 2/20 0.65
PSMD14 O00487 1/20 0.65
CDC25B P30305 1/20 0.65
PTPN7 P35236 3/20 0.65
DUSP3 P51452 3/20 0.65
DUSP6 Q16828 1/20 0.65
CTDSP1 Q9GZU7 1/20 0.64
PTPN22 Q9Y2R2 4/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
KDM4E B2RXH2 1/20 0.63
USP2 O75604 1/20 0.63
LMNA P02545 1/20 0.63
MAPT P10636 1/20 0.63
HPGD P15428 1/20 0.63
HSD17B10 Q99714 1/20 0.63
BLM P54132 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4669378 1.00 ALDH1A1 (0.81) ALDH1A1NPSR1MEN1KMT2ADNMT1
SCHEMBL4669054 0.92 ALDH1A1 (0.78) ALDH1A1NPSR1MEN1KMT2ADNMT1
SCHEMBL4669050 0.92 ALDH1A1 (0.78) ALDH1A1NPSR1MEN1KMT2ADNMT1
SCHEMBL13855947 0.91 ALDH1A1 (0.87) ALDH1A1NPSR1MEN1KMT2ADNMT1
SCHEMBL4669366 0.91 PTPN22 (0.74) ALDH1A1NPSR1MEN1KMT2ADNMT1
SCHEMBL4669368 0.91 PTPN22 (0.74) ALDH1A1NPSR1MEN1KMT2ADNMT1
SCHEMBL14103248 0.90 ALDH1A1 (0.85) ALDH1A1NPSR1MEN1KMT2ADNMT1
SCHEMBL4669224 0.89 MAPT (0.68) ALDH1A1NPSR1MEN1KMT2ADNMT1
SCHEMBL4669226 0.89 MAPT (0.68) ALDH1A1NPSR1MEN1KMT2ADNMT1
SCHEMBL13855923 0.87 MEN1 (0.79) ALDH1A1MEN1KMT2ADNMT1PSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2000140-A1 Use of derivatives of 3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine or of 3-oxo-2,3-dihydro-5H-imidazolo[3,2-a]pyrimidine for the preparation of pharmaceutical compositions intended for the treatment of cancer INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2008-12-10 EP disclosed